Ampa provides the Ampa One system, a streamlined and intuitive platform for delivering Transcranial Magnetic Stimulation (TMS) therapy. This solution is designed to be faster and more effective than existing TMS options for treating depression. The company focuses on making advanced neurological treatment more accessible and efficient for clinicians and patients.
Funding
Funding not disclosed
Founders
Product
Problem
Many individuals with depression do not respond adequately to traditional treatments like medication and psychotherapy, leaving them with persistent symptoms and reduced quality of life. Access to effective mental healthcare can also be limited by factors such as geographic location, cost, and stigma.
Solution
Ampa Health offers transcranial magnetic stimulation (TMS) therapy as a non-invasive treatment option for depression. Their approach uses targeted magnetic pulses to stimulate specific areas of the brain that are underactive in individuals with depression. This stimulation aims to restore normal brain activity and improve mood, providing an alternative for those who have not found relief through other methods. The treatment is delivered on an FDA-cleared TMS platform.
Target Audience
The primary audience includes individuals with depression who have not responded well to traditional treatments, as well as mental health professionals seeking alternative treatment options for their patients.
Features
- Non-invasive brain stimulation using targeted magnetic pulses
- FDA-cleared TMS platform
- Aims to restore activity in weakened brain regions